Freshfields Advises argenx on its $2.2bn Acquisition of Forte Biosciences

Freshfields is advising argenx (Euronext & Nasdaq: ARGX), a global immunology company, in a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion. Learn more about this transaction here.

The Freshfields team is led by Partners Oliver J. Board and Damien Zoubek and includes Senior Associate Suzie Kim and Associates Daniela Sanchez and Eponine Zhou. Partner Jeff Jay and Associates Shannon O’Hara, Juliana Zhang, Josh Rudd and Lauren McNeal are advising on life sciences matters; Partners Lori D. Goodman and Kathleen M. Emberger, Senior Associate Deena Muzafar and Associate Jonathan Saleh are advising on executive compensation and employee benefits matters; Partner Steven Matays and Associate Ryan Sweeney are advising on tax matters; Partners Mary Lehner and Christine Laciak and Associate Kate Applegate are advising on antitrust and foreign direct investment matters; Partner Stephanie Brown Cripps and David Livshiz and Associates Young Park, Cindy Gao and Taylor Jachman are advising on litigation/compliance matters; Partner John Rousakis is advising on environmental matters; Senior Associate Christine Chong and associate Matthew Johnson are advising on data privacy matters and Partner Sigrid Ververken and Principal Associate Mark Maarschalkerweerd are advising on Dutch and Belgian law matters.